Vascular Cognitive and Motor Decline: Impact of aPL
Vascular Cognitive and Motor Decline: Impact of aPL
批准号:
8234526
负责人:
Zoe Arvanitakis
金额:
$64.85万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-09-30 至 2016-08-31
关键词:
AddressAged, 80 and overAgingAntibodiesAntiphospholipid AntibodiesAutopsyBloodBlood - brain barrier anatomyBlood VesselsBlood specimenBrainC-reactive proteinCardiolipinsCell physiologyCerebrovascular DisordersCessation of lifeClinicalCognitionCognitiveCohort StudiesCommunitiesConsensusDataDiseaseElderlyEpidemiologic StudiesEpidemiologyFunctional disorderGlycoproteinsGoalsHealthHigh PrevalenceImpaired cognitionImpairmentInfarctionInflammationInternationalIschemic StrokeKnowledgeLinkLiteratureMagnetic Resonance ImagingMatrix MetalloproteinasesMeasuresMediatingMemoryMicroscopicMotorNeurologicNeurologic DysfunctionsNeuropsychological TestsOutcomePathologicPathway interactionsPerformancePermeabilityPersonsPrevalencePublic HealthResearch PersonnelRiskRoleSerineStrokeSystemic Lupus ErythematosusTestingTimeWomanaging populationcerebrovascularclinical practicecognitive functioncohortdisabilitydisorder controlfollow-upimprovedinflammatory markermenmortalitymotor impairmentnervous system disorderneuroimagingneuropathologytrendvascular factorwhite matter
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Cerebrovascular disease is among the most common neurological diseases of aging and is increasing in prevalence with changing demographic trends. The two most common consequences of cerebrovascular disease are cognitive and motor decline, which are major contributors to poor health outcomes and mortality. Identifying associated factors, particularly ones for which treatments are available, is a priority for researchers in aging. Recent data suggest that antiphospholipid antibodies (aPL) increase in aging, and are present in about 35% of persons over the age of 80 years. While aPL increase risk of stroke by about two-fold, their relation to decline in cognitive and motor function, perhaps through an association with both clinical and subclinical cerebrovascular disease, is unclear. The proposed epidemiologic study will take advantage of a cohort of 1,100 community-dwelling women and men who are followed longitudinally with a high follow-up rate, and who come to autopsy with a high autopsy rate (R01AG17917), to test the hypotheses that aPL are related to cognitive and motor decline. The study will also examine the relation of aPL to cerebrovascular disease, including subclinical cerebrovascular disease assessed by complementary ante-mortem neuroimaging and postmortem neuropathology, and the extent to which aPL are related to cognitive and motor impairment after controlling for this disease. This would suggest the existence of neurobiologic mechanisms other than cerebrovascular disease linking aPL and cognitive and motor dysfunction. Finally, because factors with effects other than vascular may influence relations, the study will examine the role of makers of inflammation and altered blood-brain barrier permeability. The proposed study, relating aPL and other markers to cognitive and motor decline, and cerebrovascular disease in older, community-dwelling persons, will provide new knowledge regarding the role of aPL in common neurological conditions of aging. Because aPL are common vascular factors for which treatments are available, this study will provide new data which has the potential to improve public health by shifting current clinical practice paradigms and reducing the burden of neurological disease in aging.
PUBLIC HEALTH RELEVANCE: Cerebrovascular disease is increasing in prevalence with the aging population, and cognitive and motor decline, its' two most common consequences, are both major contributors to poor health outcomes and mortality. Identification of associated factors is priority for researchers in aging. These study relating blood vascular factors to cognitive and motor decline, and cerebrovascular disease, will fill a gap in knowledge in the field and has potential to provide data which will improve public health. an important
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Brain cPLA2 as a mechanism for neuroinflammation in AD/ADRD with and without APOE4
-
批准号:10464564
-
项目类别:
-
资助金额:$241.77万
-
财政年份:2022
-
负责人:Zoe Arvanitakis
-
依托单位:
The role of blood and brain 5-hydroxymethylcytosine in linking vascular risk factors to ADRD in older White and Black persons
-
批准号:10315659
-
项目类别:
-
资助金额:$327.52万
-
财政年份:2021
-
负责人:Zoe Arvanitakis
-
依托单位:
Vascular Cognitive and Motor Decline: Impact of aPL
-
批准号:8336938
-
项目类别:
-
资助金额:$61.5万
-
财政年份:2011
-
负责人:Zoe Arvanitakis
-
依托单位:
Vascular Cognitive and Motor Decline: Impact of aPL
-
批准号:8881036
-
项目类别:
-
资助金额:$52.74万
-
财政年份:2011
-
负责人:Zoe Arvanitakis
-
依托单位:
Vascular Cognitive and Motor Decline: Impact of aPL
-
批准号:8728095
-
项目类别:
-
资助金额:$58.44万
-
财政年份:2011
-
负责人:Zoe Arvanitakis
-
依托单位:
Vascular Cognitive and Motor Decline: Impact of aPL
-
批准号:8526334
-
项目类别:
-
资助金额:$57.29万
-
财政年份:2011
-
负责人:Zoe Arvanitakis
-
依托单位:
Oxidative Stress, Aging and Alzheimer's Disease
-
批准号:7556333
-
项目类别:
-
资助金额:$15.55万
-
财政年份:2005
-
负责人:Zoe Arvanitakis
-
依托单位:
Oxidative Stress, Aging and Alzheimer's Disease
-
批准号:7007680
-
项目类别:
-
资助金额:$15.53万
-
财政年份:2005
-
负责人:Zoe Arvanitakis
-
依托单位:
Oxidative Stress, Aging and Alzheimer's Disease
-
批准号:7367080
-
项目类别:
-
资助金额:$15.49万
-
财政年份:2005
-
负责人:Zoe Arvanitakis
-
依托单位:
Oxidative Stress, Aging and Alzheimer's Disease
-
批准号:6868496
-
项目类别:
-
资助金额:$15.56万
-
财政年份:2005
-
负责人:Zoe Arvanitakis
-
依托单位:
Oxidative Stress, Aging and Alzheimer's Disease
-
批准号:7173442
-
项目类别:
-
资助金额:$15.52万
-
财政年份:2005
-
负责人:Zoe Arvanitakis
-
依托单位: